MarketBeat
04 Jun 2026, 04:02 UTC · 3h ago
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Search tags
MarketBeat
04 Jun 2026, 04:02 UTC · 3h ago
Search tags
Story key points
5 claims · impact-rated
Amphastar launched a generic version of Atrovent and is currently the sole generic on the market, with a potential $40 million in annual sales. — Sole-provider status for a high-barrier generic creates a significant, immediate revenue stream and competitive moat for several years.
+0.60The company implemented a third-party service in May to eliminate approximately 80% of 'double discounting' pricing pressure affecting BAQSIMI. — Addressing a 20% pricing decrease in Q1 suggests a recovery of margins and revenue starting in Q2 and Q3.
+0.40Amphastar expects to launch a biosimilar insulin aspart in 2027, targeting a potential $25 million to $50 million in annual sales if interchangeability is granted. — While high potential, this is a long-term catalyst (2027) with regulatory uncertainty regarding the 'interchangeable' designation.
+0.30Continue reading
6 related stories
Amphastar is maintaining its mid- to high-single-digit revenue growth expectations for 2026. — Confirms management's confidence in the growth trajectory despite short-term pricing headwinds.
+0.20The company plans to discontinue BAQSIMI sales in five or six international markets starting July 1 due to losses from low prices and regulatory costs. — Marginally positive for the bottom line as it removes loss-making operations, though it reduces global footprint.
+0.10Ticker attribution
Model heads
The company has strong growth drivers in a new generic launch and a promising biosimilar pipeline, despite some pricing pressures on BAQSIMI.
Mentioned only as the previous owner of BAQSIMI with no current financial or operational impact discussed.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
5h ago
